<code id='85F807557B'></code><style id='85F807557B'></style>
    • <acronym id='85F807557B'></acronym>
      <center id='85F807557B'><center id='85F807557B'><tfoot id='85F807557B'></tfoot></center><abbr id='85F807557B'><dir id='85F807557B'><tfoot id='85F807557B'></tfoot><noframes id='85F807557B'>

    • <optgroup id='85F807557B'><strike id='85F807557B'><sup id='85F807557B'></sup></strike><code id='85F807557B'></code></optgroup>
        1. <b id='85F807557B'><label id='85F807557B'><select id='85F807557B'><dt id='85F807557B'><span id='85F807557B'></span></dt></select></label></b><u id='85F807557B'></u>
          <i id='85F807557B'><strike id='85F807557B'><tt id='85F807557B'><pre id='85F807557B'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:5349
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In